Jump to content

Izencitinib

From Wikipedia, the free encyclopedia

Izencitinib
Identifiers
  • 3-[(1R,5S)-3-[[7-[(5-methyl-1H-pyrazol-3-yl)amino]-1,6-naphthyridin-5-yl]amino]-8-azabicyclo[3.2.1]octan-8-yl]propanenitrile
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H26N8
Molar mass402.506 g·mol−1
3D model (JSmol)
  • CC1=CC(=NN1)NC2=NC(=C3C=CC=NC3=C2)NC4C[C@H]5CC[C@@H](C4)N5CCC#N
  • InChI=1S/C22H26N8/c1-14-10-21(29-28-14)26-20-13-19-18(4-2-8-24-19)22(27-20)25-15-11-16-5-6-17(12-15)30(16)9-3-7-23/h2,4,8,10,13,15-17H,3,5-6,9,11-12H2,1H3,(H3,25,26,27,28,29)/t15?,16-,17+
  • Key:DADAEARVGOQWHV-ALOPSCKCSA-N

Izencitinib (TD-1473) is a drug which acts as a pan-Janus kinase inhibitor, binding with high affinity at all three subtypes JAK1, JAK2 and JAK3. It is taken orally and was developed to be gut selective with minimal absorption into the rest of the body, allowing targeting of inflammatory bowel disease but with reduced side effects compared to other similar drugs.[1][2]

See also

[edit]

References

[edit]
  1. ^ Roda G, Dal Buono A, Argollo M, Danese S (September 2020). "JAK selectivity: more precision less troubles". Expert Review of Gastroenterology & Hepatology. 14 (9): 789–796. doi:10.1080/17474124.2020.1780120. PMID 32520647.
  2. ^ Hardwick RN, Brassil P, Badagnani I, Perkins K, Obedencio GP, Kim AS, et al. (March 2022). "Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species". Toxicological Sciences. 186 (2): 323–337. doi:10.1093/toxsci/kfac002. PMC 8963331. PMID 35134999.